Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record.

Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia

Rubnitz, Jeffrey E., Raimondi, Susana C., Tong, Xin, Srivastava, Deo Kumar, Razzouk, Bassem I., Shurtleff, Sheila A., Downing, James R., Pui, Ching-Hon, Ribeiro, Raul C., Behm, Frederick G.·2002·Journal of Clinical Oncology

Abstract

PURPOSE: To determine the impact of MLL rearrangements on the outcome of children with acute myeloid leukemia (AML). PATIENTS AND METHODS: We analyzed the clinical and biologic features of 298 infants and children with primary AML treated on four consecutive institutional clinical trials. The Kaplan-Meier method was used in survival analysis and the Cox proportional-hazards model was used to analyze the effect of potential prognostic factors on event-free survival (± 1 SE). RESULTS: Molecular studies of 152 cases detected 42 with MLL rearrangements. The karyotypes of these 42 revealed the t(9;11) (15 cases), abnormalities of chromosomes 10 and 11 (nine cases), the t(11;19) (four cases), other abnormalities of 11q23 (seven cases), and miscellaneous rearrangements (seven cases). Among these 42 patients, the 15 whose leukemic cells carried the t(9;11) had a better outcome (66% ± 15%) than the other 27 (25.9% ± 11.2%; P = .004). Cases with the t(9;11) were also characterized by M5 AML morphology (21 of 23 cases). Of the 63 patients with M5 AML, the 21 whose leukemic cells demonstrated the t(9;11) had a better outcome (71.1% ± 11%) than the other 42 (25.8% ± 7.9%; P = .0004). The only independent factors indicating a favorable prognosis were presenting leukocyte count less than 50 × 10 9 /L (relative risk of relapse, 0.73; 95% confidence interval, 0.55 to 0.97; P = .03) and the t(9;11) (relative risk of relapse, 0.32; 95% confidence interval, 0.16 to 0.64; P = .002). CONCLUSION: We conclude that the t(9;11) is the most favorable genetic factor for patients with AML treated at our institution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2002.08.023

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 225

Metadata

Authors
Rubnitz, J. E., Raimondi, S. C., Tong, X., Srivastava, D. K., Razzouk, B. I., Shurtleff, S. A., Downing, J. R., Pui, C.-H., Ribeiro, R. C., & Behm, F. G.
Venue
Journal of Clinical Oncology
Published
2002-05
Volume
20
Issue
9
Pages
2302-2309
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2155891710
Cited by
225
References
0
FWCI
8.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2002.08.023
The paper
Rubnitz, J. E., Raimondi, S. C., Tong, X., Srivastava, D. K., Razzouk, B. I., Shurtleff, S. A., Downing, J. R., Pui, C.-H., Ribeiro, R. C., & Behm, F. G. (2002). Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.08.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.